Last reviewed · How we verify
NCT07031674
Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.
trial in Lupus Nephritis in 56 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | Yipeng Liu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 October 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Lupus Nephritis — all drugs for Lupus Nephritis →
- Belimumab — all drugs for Belimumab →
Sponsor
Yipeng Liu
Who can join
Adults 18 to 65, any sex, with Lupus Nephritis or Belimumab. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to compare the efficacy and safety of telitacicept and belimumab in the treatment of lupus nephritis in patients aged 18-65 years with lupus nephritis. The main question it aims to answer is: What are the response rates of the two drugs for the main renal therapy in the lupus nephritis population? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07031674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lupus Nephritis
Currently open trials in the same condition.
- NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
- NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
- NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting
Other Yipeng Liu trials
Trials by the same sponsor.
- NCT07069972 — A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimum · not yet recruiting
- NCT07053137 — A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythema · active not recruiting
- NCT05656963 — The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD · unknown
- NCT06123871 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value · unknown
- NCT06097351 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of Its Clinical Diagnostic Value · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07031674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yipeng Liu
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07031674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing